Bulletin
Investor Alert

Market Pulse Archives

Oct. 15, 2018, 7:39 a.m. EDT

EyePoint Pharma shares jump on FDA approval of Yutiq implant

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    EyePoint Pharmaceuticals Inc. (EYPT)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

EyePoint Pharmaceuticals Inc. shares /zigman2/quotes/210537129/composite EYPT +0.18% soared 8% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved its Yutiq implant for the treatment of uveitis, a leading cause of blindness. Yutiq is a micro-insert that is designed to release fluocinolone acetonide over a three-year period and that can be administered in a doctor's office. :Chronic non-infectious uveitis affecting the posterior segment of the eye is the third leading cause of blindness in the U.S.," Chief Executive Nancy Lurker said in a statement. The company is expecting to launch the product in the first quarter of 2019. EyePoint shares have gained 199% in 2018, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.73% has gained 3.5%.

/zigman2/quotes/210537129/composite
US : U.S.: Nasdaq
$ 11.11
+0.02 +0.18%
Volume: 143,339
Aug. 12, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$378.54 million
Rev. per Employee
$337,089
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,280.15
+72.88 +1.73%
Volume: 2.22B
Aug. 12, 2022 6:27p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.